FDA Grants Priority Review To Merck's Application For Keytruda (Pembrolizumab) Plus Concurrent Chemoradiotherapy For Newly Diagnosed High-risk Locally Advanced Cervical Cancer; The Prescription Drug User Fee Act Date Of January 20, 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted priority review to Merck's application for Keytruda, in combination with concurrent chemoradiotherapy, for the treatment of newly diagnosed high-risk locally advanced cervical cancer. The Prescription Drug User Fee Act date is set for January 20, 2024.
September 20, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's Keytruda has received FDA priority review for use in treating high-risk locally advanced cervical cancer. This could potentially lead to increased sales and revenue for Merck.
The FDA's priority review of Merck's Keytruda for treating high-risk locally advanced cervical cancer could potentially lead to faster approval and market entry. This could result in increased sales and revenue for Merck, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100